BG
AIMT

BlackRock Group’s Aimmune Therapeutics AIMT Stock Holding History

BlackRock Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$103K Sell
5,042
-2,763
-35% -$56.5K ﹤0.01% 2827
2016
Q3 		$117K Buy
7,805
+981
+14% +$13.2K ﹤0.01% 2789
2016
Q2 		$74K Buy
6,824
+4,867
+249% +$66.1K ﹤0.01% 2853
2016
Q1 		$27K Buy
+1,957
New +$30.5K ﹤0.01% 3005

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Group's AIMT Position: Q4 2016 in Review

BlackRock Group reduced its Aimmune Therapeutics (AIMT) stake by 35% in Q4 2016, selling an estimated $56.5K and leaving 5,042 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #2827.

BlackRock Group first reported a position in AIMT in Q1 2016 and has held it in 4 quarters since. The position peaked at $117K in Q3 2016. 92 funds tracked by Wall St. Rank hold AIMT as of Q4 2016.

  • BlackRock Group held 5,042 shares of Aimmune Therapeutics worth $103K as of Q4 2016.
  • BlackRock Group sold 2,763 Aimmune Therapeutics shares in Q4 2016, an estimated $56.5K.
  • Aimmune Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2827 holding.
  • BlackRock Group first reported a position in Aimmune Therapeutics in Q1 2016 and has held it in 4 quarters since.
  • BlackRock Group's Aimmune Therapeutics position peaked at $117K in Q3 2016.
  • 92 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.